Grifols has been granted a patent for fusion proteins involving PD1 and PD-L1 extracellular domains for monitoring biotherapeutic antibodies in immunoassays. The patent also covers a method to determine biotherapeutic antibody levels in patients post-immunotherapy. GlobalData’s report on Grifols gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Grifols SA - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Grifols, Attenuated virus-based vaccines was a key innovation area identified from patents. Grifols's grant share as of February 2024 was 52%. Grant share is based on the ratio of number of grants to total number of patents.

Fusion proteins for monitoring biotherapeutic antibodies in immunoassays

Source: United States Patent and Trademark Office (USPTO). Credit: Grifols SA

The granted patent (Publication Number: US11919938B2) discloses a fusion protein that includes an extracellular domain of a human Programmed Cell Death-1 (PD-1) protein, or a fragment thereof, which binds to a human PD-L1 protein. This fusion protein also contains an oligomerization domain selected from a p53 tetramer domain or a fragment of the p53 tetramer domain. The extracellular domain of the PD-1 protein is linked to the oligomerization domain through peptide linkers with specific amino acid sequences.

Furthermore, the patent claims specify the amino acid sequences of the extracellular domain of PD-1 that share at least 70% homology with certain sequences. The fusion protein described in the patent is designed to have a higher reactivity against an anti-PD1 antibody compared to monomer or dimer oligomerization domains. Additionally, the patent includes a method for determining the levels of biotherapeutic antibodies like nivolumab and pembrolizumab in patient samples by using the fusion protein. This method involves obtaining a sample from a patient undergoing antibody treatment and then contacting the sample with the fusion protein to measure the circulating levels of the biotherapeutic antibody accurately.

To know more about GlobalData’s detailed insights on Grifols, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies